Synonyms: ABT-199 | GDC-0199 | Venclexta® | Venclyxto®
venetoclax is an approved drug (FDA and EMA (2016))
Compound class:
Synthetic organic
Comment: Venetoclax is a BH3 mimetic that selectively targets Bcl-2 [4], utilised for its pro-apoptotic activity. It is noteworthy that venetoclax is the first approved medicine designed to induce a natural process that helps cells self-destruct.
The IUPAC name provided by PubChem matches 'Example 5' claimed in patent US8580794 [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Bcl-2, is an antiapoptotic protein that is central to the survival of chronic lymphocytic leukemia cells in which it is often pathologically overexpressed. Venetoclax inhibits this antiapoptotic functionality and restores apoptotic balance, which leads to tumour cell death. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Asthma |
Disease Ontology:
DOID:2841 OMIM: 600807 |
Venetoclax (ABT-199) has been shown to induce apoptosis of airway inflammatory cells (eosinophils, neutrophils, Th2, Th17 and dendritic cells) suggesting a potiential role in management of eosinophilic or corticosteroid resistant-neutrophilic airway inflammation. | 5 |
Chronic lymphocytic leukemia |
Disease Ontology:
DOID:1040 OMIM: 151400 Orphanet: ORPHA67038 |
Approved drug for CLL with or without 17p deletion. | 2 |